The National Hepatology and Tropical Research medicine institute
Cairo, Egypt
NCT Number: NCT04468685
Laparoscopic cholecystectomy (LC) is an easy procedure characterized by its minimal invasiveness, less post-operative pain and early recovery when compared to the open conventional cholecystectomy. However, patients who have undergone LC still complain of postoperative pain. It has been reported that ondansetron produces numbness when injected under the skin and has local anesthetic effect that is 15 times more potent than lidocaine the most widely used local anesthetic and probably explains its antiemetic action. It possesses anti-inflammatory, anesthetic, and analgesic properties by its multifaceted actions as a 5-HT3 receptor antagonist, a Na channel blocker, and a mu-opioid agonist which may have a potential role in decreasing pain. The study aimed to demonstrate the effectiveness of IP administration of ondansetron on pain management post LC.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 2
Cairo, Egypt
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Interperitoneal administration in the gall bladder bed
Interperitoneal administration in the gall bladder bed
Time frame: 24 hours
National Hepatology & Tropical Medicine Research Institute
Other Gov
Efficacy of Intraperitoneal Ondansetron Administration on Pain Relief After Laparoscopic Cholecystectomy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06005701
Behavior, Bile Duct Diseases
Buraidah, Al-Qassim Region, Saudi Arabia
View Trial DetailsNCT06502028
Biliary Tract Diseases, Cholecystitis
Seoul, South Korea
View Trial DetailsNCT06198335
Biliary Tract Diseases, Cholecystitis
Bursa, Turkey (Türkiye)
View Trial DetailsNCT06981052
Biliary Tract Diseases, Cholecystitis
Worcester, Massachusetts, United States
View Trial Details